IL-17 antagonist compositions for treating inflammatory arthritis
Summary
USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.
What changed
USPTO issued patent grant US12594333B2 to Novartis AG for compositions and methods of treating inflammatory arthritis using IL-17 antagonists including secukinumab. The patent covers IL-17 binding molecules and receptor binding molecules as therapeutic agents. The filing date was February 24, 2025, and the grant date is April 7, 2026.
For pharmaceutical companies and healthcare providers, this patent establishes exclusive rights that may affect licensing negotiations, generic drug development timelines, and therapeutic approach selections for inflammatory arthritis patients. Novartis gains 20-year patent protection for these therapeutic regimens in the United States.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods of treating inflammatory arthritis using IL-17 antagonists
Grant US12594333B2 Kind: B2 Apr 07, 2026
Assignee
NOVARTIS AG
Inventors
Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
Abstract
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
CPC Classifications
A61K 39/3955 A61K 2039/505 C07K 2317/76 A61P 17/06 A61P 19/02
Filing Date
2025-02-24
Application No.
19061831
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.